Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
February 02 2021 - 8:00AM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage
company developing transformative therapies for the treatment of
cancer and rare diseases with significant unmet needs, today
announced the appointment of Cynthia Smith to its Board of
Directors. Ms. Smith brings to Protara over 20 years of diverse
leadership experience within the healthcare industry, most recently
serving as Chief Commercial Officer at ZS Pharma.
“It is with great excitement that we welcome
Cynthia to our Board of Directors,” said Jesse
Shefferman, Chief Executive Officer
of Protara Therapeutics. “As an accomplished
leader with a proven track record in key commercial and strategic
roles at several leading biopharmaceutical organizations, we look
forward to leveraging Cynthia’s unique insights as we continue to
work toward establishing a path to market in the U.S. for TARA-002
for the treatment of lymphatic malformations and advancing our
non-muscle invasive bladder cancer program.”
“Protara holds great promise in its mission to
develop transformative therapies for the treatment of cancer and
rare diseases,” said Ms. Smith. “I look forward to working
alongside the talented management team and Board to help drive
Protara’s continued growth and create value-enhancing opportunities
for its shareholders.”
While in her role as Chief Commercial Officer at
ZS Pharma, Ms. Smith led the company’s transition from a
development stage company to a commercial organization. Prior to
joining ZS Pharma, she served as Vice President, Market Access and
Commercial Development at Affymax, Inc. Earlier, she held various
senior leadership positions in market access, corporate strategy,
government relations and external affairs at Merck & Co. Before
beginning her career in the biopharmaceutical industry, Ms. Smith
served as a Healthcare Policy Analyst in the White House Office of
Management and Budget. She currently serves on the Board of
Directors at Spero Therapeutics, Dicerna Pharmaceuticals, and
Akebia Therapeutics. She earned a B.A. from the University of North
Carolina at Chapel Hill, an M.B.A. from the Wharton School and an
M.S. in public policy from the Eagleton Institute of Politics at
Rutgers University.
About Protara Therapeutics,
Inc.
Protara is committed to identifying and
advancing transformative therapies for people with cancer and rare
diseases with limited treatment options. Protara’s portfolio
includes its lead program, TARA-002, an investigational cell-based
therapy being developed for the treatment of non-muscle invasive
bladder cancer and lymphatic malformations, and IV Choline
Chloride, an investigational phospholipid substrate replacement
therapy for the treatment of intestinal failure-associated liver
disease. For more information, visit www.protaratx.com.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are "forward
looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Protara may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “designed,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words or expressions referencing future events, conditions or
circumstances that convey uncertainty of future events or outcomes
to identify these forward-looking statements. Such forward-looking
statements include but are not limited to, statements regarding
Protara’s intentions, beliefs, projections, outlook, analyses or
current expectations concerning, among other things: statements
regarding Protara’s business strategy, Protara’s development plans
for its product candidates and the contribution of Ms. Smith’s
experience and past achievements in helping us achieve our
strategic objectives, including the advancement of our programs.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Factors that contribute
to the uncertain nature of the forward-looking statements include
risks and uncertainties associated with: Protara’s development
programs, including the initiation and completion of non-clinical
studies and clinical trials and the timing of required filings with
the FDA and other regulatory agencies; the impact of the COVID-19
pandemic on Protara’s business and the global economy; general
market conditions; changes in the competitive landscape; changes in
Protara’s strategic and commercial plans; Protara’s ability to
obtain sufficient financing to fund its strategic plans and
commercialization efforts; the loss of key members of management;
and the risks and uncertainties associated with Protara’s business
and financial condition in general, including the risks and
uncertainties described more fully under the caption "Risk Factors"
and elsewhere in Protara's filings and reports with the United
States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management's
assumptions and estimates as of such date. Protara undertakes no
obligation to update any forward-looking statements, whether as a
result of the receipt of new information, the occurrence of future
events or otherwise, except as required by law.
Company Contact:
Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Apr 2023 to Apr 2024